NCCMP Hot Topics: New Drugs for Weight Loss Telehealth Update Peri-COVID

September 13, 2023


Presenters: Sadhna Paralkar, MD / Eileen Pincay RPh, Moderator: Breanna Radtke

© 2023 by The Segal Group, Inc.

Weight Loss



The Obesity Rate of the U.S. Population Has Almost Doubled in Recent Decades



Source: Centers for Disease Control and Prevention. Health, United States, 2020-2021

Segal 3

What are GLP-1 Medications?

GLP-1 is a hormone found naturally in our bodies that targets the area of the brain that regulates appetite and is insufficient in people who have type 2 diabetes.

Diabetes

Medications mimic GLP-1 hormone and help lower blood sugar Weight Loss Medications mimic GLP-1 hormone and help regulate appetite




History of GLP-1 Medications

Until recently GLP-1's considered a second-line agent to treat diabetes 2021, ADA recommends prescribing GLP-1s to reduce health complications regardless of A1C or metformin use 2023 ADA guidelines emphasizes both supporting higher weight loss and focusing on obesity as chronic disease

Led to increased utilization of GLP-1s for diabetes AND weight loss



Plan Spending on Anti-Diabetic Medications with Weight Loss is Rising Steadily




Source: Segal SHAPE, Segal's data warehouse, 2018 to 2022

```
🔆 Segal 🛛 🤅
```

Off-Label Weight-Loss Drug Usage

2021 – 2022 GLP-1 Utilizer History¹



7

1. Historical lookback began with date of first GLP-1 medication fill, members may have utilization of more than 1 medication in this class subsequently


Utilization Concerns

- Off label use of diabetes GLP-1 therapies (i.e. Ozempic) for weight loss
- Social media has been a big contributor to using Ozempic for weight loss which, in turn, has caused drug shortages.
- PBMs are offering utilization management programs to curb off-label spend for the GLP-1 medications.
- GLP-1s are likely to become the number one drug cost therapy for many plan sponsors by 2024.



Obesity GLP-1 Medication Costs Compared to Diabetes GLP-1 Medications


30-day Rx Cost [2023 YTD]



Note that prices listed are mean charges after PBM discounts but before rebate offsets



Dramatic Increase in Anti-Obesity Medication Spending due to GLP-1s



Various PBM Cost Management Strategies

Smart logic to screen out patients who have

Use utilization management to ensure the diabetic GLP-1 drugs are only used for patients with diabetes

2 3


(if available) and prescription claims history to bypass PA requirements. Doctor office to confirm diagnosis and "attest" to it in a PA

diabetes. Smart logic utilizes both ICD diagnosis codes

Doctor office to confirm diagnosis and "attest" to it in a PA case

Move from step therapy to prior authorization approach

Be sure to consider any potential rebate impact




X Segal 11


Are Plans Covering Weight Loss Drugs and What Is Impact?

- Employers Health, a large group-purchasing organization for pharmacy benefits for 2021 reported 60% of clients exclude obesity drugs and 25% cover them with a PA.
- Medicare does not cover obesity drugs, but does cover bariatric surgery and intensive behavioral therapy
- In 2018, the average cost for Segal clients who cover weight-loss medications was \$0.50 PMPM and by 2022, it was \$2.21 PMPM.

https://info.mmitnetwork.com/hubfs/AHD%20Friday%20Infographics/coverage-of-weight-lossmedications.png?utm_campaign=AIS%20Health%20Daily&utm_medium=email&_hsmi=242188090&_hsenc=p2ANqtz-9Pg2vwJx5BQiFjoGmxuIMvtw1Dy-WX_AF11dsJXR7fkZ40UHPED7MsLUJPm-OpsmEmdGy52x_QWIURo8hTY8OLTja56g&utm_content=242188090&utm_source=hs_email



Plan Spending on Weight-Loss Medication Continues to Shift Towards GLP-1s



Weight-loss Options Vary in Cost and Effectiveness

	Traditional Diet & Exercise Programs	Provider-Led Clinical Weight Loss	GLP-1 Drugs	Bariatric Surgery
Avg weight loss at ~ 1 year (% reduction in body weight)	0–5%	13%	15%+	20%+
Est. List Price (for one year of treatment)	\$500	\$1,800	\$12,000+	\$20,000+
	Chin, S., Keum, C., Woo, J. et al. Successful weight reduction and maintenance by using a smartphone application in those with overweight and obesity. Sci Rep. 2016; 6, 34563, Noom list price	NcKenzie AL, et al. Nutrients. 2021; 13(3):749 Outcomes among one year completers, Virtaust price	Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Novo Nordisk; list price. https://www.novocare.com/wegovy/let-us-help/ explaining-list-price.html - \$1309.42 per	NTMC, "How much does bariatric surgery cost," Accessed 1/25/2023, Maciejewski ML, Arterburn DE, Van Scoyoc L, Smith VA, Yancy WS Jr, Weidenbacher HJ, Livingston EH, Olsen MK. Bariatric Surgery and Long-term Durability of Weight Loss. JAMA Surg. 2016 Nov 1;151

package. Accessed 10/18/22



Steps in Managing GLP-1 Spend



Acquire Rx

- Program eligibility
- Health coaching PA •
- Bridge to Physician .
- Troubleshoot access ٠







- Trust as foundation
- Match and move .
- Guiding adherence .
- Monitoring efficacy •



Titrate Rx

- Objective weight loss
- Sustained behavior change ٠
- Other condition improvements .
- Support Physicians/participants .



Sustained Weight Loss

- Ongoing Coach relationship ٠
- Continued data monitoring .
- Generalizable skills/strategies .

🕂 Segal

15

Maximization of resources .

The Bigger Picture for Managing Obesity

- Assess and reevaluate current obesity treatments under the medical benefit.
- Update patient education and access to lifestyle weight-loss programs
- Offer access to low-cost fitness programs
- Implement UM guidelines for all AOMs
- Require patients to be in a behavioral health management program



The Bigger Picture for Managing Obesity

- Negotiate lowest-net-cost PBM formulary changes
- Provide educational support for appropriate and safe exercising.
- Offer access to virtual coaching
- Implement accountability check-ins with patients
- Consider implementing stricter coverage to target smaller group of plan participants
- Seek outcomes based performance guarantees with PBMs when adding coverage of these high cost anti-obesity meds tied to achieving minimum average weight loss amounts (e.g. at least 10% weight loss after 6 months use).

Need for Health Coaching

- Needs whole person care, not just medication access
- Health coaching is of paramount importance in order to:
 - Build ongoing, trusted relationship with the recipient of the medication
 - Monitor the medication side effects and interactions
 - Address the medication goal areas and adherence
 - Discuss dosages, interactions, side effects and concerns related to the medication
 - Can advocate, speak directly with physician or pharmacy
 - Monitor and help manage medication tolerance and contraindications
 - Could be in person or virtual



Goal: Sustainable Weight Loss


- Continued behavior change coaching for 1-2 years post treatment
- Build and activate ongoing support network for each participant
- Learned and lasting behavior change
 - Weight management
 - Nutrition advice
 - Exercise advice
 - Medication adherence
 - Stress, sleep, other disease state management
- Importance of physical health and wellbeing is established
- Relapse prevention



Telehealth Update – peri-COVID



Telehealth Impact



Conditions with the greatest increase in visits

Rank	Category	Change
	Trauma- and stressor-related	
1	disorders	42,018%
2	Feeding and eating disorders	34,703%
	Obsessive-compulsive and related	
3	disorders	34,177%
4	Alcohol-related disorders	27,878%
5	Medical examination/evaluation	24,571%
6	Anxiety and fear-related disorders	24,527%
7	Multiple sclerosis	21,920%
8	Cannabis-related disorders	18,440%
9	Depressive disorders	17,912%
10	Neurodevelopmental disorders	14,469% ₁


Variation in telehealth adoption by US State

	State	Payment Parity	% Telehealth Adoption
Top 10 States	Hawaii	Yes	22%
	California	Yes	20%
	District of Columbia	No	19%
	Massachusetts	Yes	17%
	Oregon	No	14%
	Maryland	Yes	13%
	Delaware	Yes	12%
	Rhode Island	Yes	12%
	Vermont	Yes	12%
	Connecticut	Yes	12%
	Mississippi	No	7%
S	Missouri	No	6%
te	Alaska	No	6%
Bottom 10 States	Alabama	No	6%
	Tennessee	No	6%
	Montana	No	6%
	South Dakota	No	5%
	North Dakota	No	5%
	Nebraska	Yes	5%
	lowa	Yes	4%




Trends in outpatients via telemedicine

Telehealth Trend by Medical Specialty



23

Trends in outpatients via telemedicine



Source: Telehealth Adoption after Pandemic

Segal 24



- Should plan sponsors consider potential long-term health savings from lower obesity rates vs. higher near-term Rx costs today?
- Are these drugs more effective from both outcome and cost perspectives, than bariatric surgery?
- Can the plan limit coverage for these drugs to a specific BMI, such as 40+?
- If a plan covers weight loss drugs, how long before they are likely to see an ROI from all of illnesses associated with obesity.
- Should we encourage or discourage use of obesity fighting drugs?
- What's Telehealth going to look like in 2030?

Impact of Insulin Price Decreases



Insulin – New Drug Pricing Dynamics

- In March 2023, the three leading insulin manufacturers (Lilly, Novo Nordisk, and Sanofi) announced major price decreases of up to 75% for some of their insulin products.
- Starting January 1, 2024, the American Rescue Plan Act will remove the rebate cap which affects what manufacturers pay.
- This in turn will have an impact on the rebates paid by manufacturers to PBMs and rebate aggregators.
- PBMs are approaching this pricing update in various ways.

Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at \$35 Per Month

News Release

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-ofpocket Lantus costs at \$35 for all patients with commercial insurance

March 16, 2023

US PRESS RELEASE

Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024



Thank You

Eileen Pincay, RPh Vice President and National Pharmacy Practice Leader epincay@segalco.com

Sadhna Paralkar, MD Senior Vice President and National Medical Director SParalkar@segalco.com





